Market research
DRRX Durect Corporation
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 59M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- 0.93
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US2666055007
- Market cap
- 59M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- 0.93
About
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DRRX discussion.
5 years, 4 months ago
DURECT Corporation is currently in a long term downtrend where the price is trading 23.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
DURECT Corporation's total revenue sank by 111.1% to $-1M since the same quarter in the previous year.
Its net income has increased by 203.0% to $4M since the same quarter in the previous year.
Finally, its free cash flow fell by 315.4% to $-8M since the same quarter in the previous year.
Based on the above factors, DURECT Corporation gets an overall score of 2/5.